Pharmacogenomic Selection of Antidepressants

Pharmacogenomic testing has been widely available for over a decade to help guide pharmacotherapy including antidepressant selection when treating major depressive disorder. Yet, the data hasn’t substantiated improved safety or efficacy. Host Geoff Wall is joined by Sarah Grady, PharmD to evaluate the PRIME study looking at the role of pharmacogenomic testing in depression.The GameChanger Pharmacogenomic testing may help decrease adverse effects at 12 weeks, but not 24 weeks. However, the study did identify a potential confounder with L-methylfolate deficiency.Show Segments 00:00 – Introductions 02:15 – Background on Pharmacogenomic Testing05:15 – PRIME Care Study 18:10 – Connecting to Practice20:55 – Gamechanger22:12 – L-methylfolate Deficiency Treatment26:25 – Closing Remarks Host Geoff Wall, PharmD, BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health GuestSarah Grady, PharmDProfessor of Pharmacy Practice, Drake UniversityReferences and resources:Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. Redeem your CPE or CME creditCPE (Pharmacist) CME (Physician) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a Membership Prescribers: Get a Membership  Continuing Education Information:Learning Objectives:1. Describe the outcomes and limitations of the PRIME care study2. Discuss the role of L-methylfolate in the treatment of depressionAll relevant financial relationships have been mitigated.  0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-22-305-H01-PInitial release date: 09/05/22Expiration date: 09/05/2023Additional CPE & CME details can be found hereFollow CEimpact on Social Media:LinkedInInstagram